• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHEN Chen,LI Xia,DONG Yan,WANG Yongjing.Pharmaceutical care of a patient with acute lymphoblastic leukemia in combination with imatinib and voriconazole[J].Journal Of Pharmaceutical Research,2022,41(10):686-689[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2065times   Download 2155次 QR Code for this article
Scan with your phone!
1例临床药师参与伊马替尼与伏立康唑联合用药的药学监护
陈晨1,李霞2,董艳1,王永静3
Font:Larger+|Default|Smaller-
(1.山东大学第二医院临床药学科,山东 济南 250033;2.山东省药品不良反应监测中心,山东 济南 250014;3.山东大学第二医院血液内科,山东 济南 250033)
摘要:
目的 为伊马替尼与伏立康唑的联合用药提供药物用量调整思路。方法 对临床药师全程参与的1例费城染色体阳性的急性淋巴细胞白血病患者的治疗过程进行分析。该患者在伊马替尼治疗期间合并真菌感染,临床药师从药物的代谢特点、安全性等方面考虑,建议采用伏立康唑联合伊马替尼治疗,但需对伊马替尼进行剂量调整;结合患者病情将伊马替尼调整至每天0.2 g,后增加至每天0.3 g,并对伊马替尼进行血药浓度测定;联合用药期间评估和监测治疗过程中的药物不良反应。结果 医师采纳了临床药师的建议。采用伏立康唑联合伊马替尼联合用药期间,患者的感染得到了良好控制。伊马替尼血药浓度显示1 372.08 ng·mL-1,监测患者肝功能、血常规等正常,病情平稳。结论 临床药师参与了该患者的治疗过程,为其制订了个体化的治疗方案并取得了良好的效果,为伊马替尼与伏立康唑的联合用药提供药物用量调整思路。
关键词:  急性淋巴细胞白血病  伊马替尼  伏立康唑  临床药师  药学监护
DOI:10.13506/j.cnki.jpr.2022.10.012
基金项目:山东省药品化妆品不良反应监测哨点课题(No.2021SDADRKY04)
Pharmaceutical care of a patient with acute lymphoblastic leukemia in combination with imatinib and voriconazole
CHEN Chen1,LI Xia2,DONG Yan1,WANG Yongjing3
(1. Department of Clinical Pharmacy, the Second Hospital of Shandong University, Jinan 250033,China;2. Shandong Center for Adverse Drug Reaction Monitoring, Jinan 250014,China;3. Department of Hematology, the Second Hospital of Shandong University, Jinan 250033,China)
Abstract:
Objective To provide ideas for adjusting the dosage of imatinib and voriconazole in combination.Methods The treatment of 1 case of Philadelphia chromosome positive acute lymphoblastic leukemia participated by clinical pharmacists were analyzed. The patient was diagnosed for fungal infection during imatinib treatment. Considering the metabolic characteristics and safety of the drug, the clinical pharmacist recommended voriconazole combined with imatinib for treatment, but the dose of imatinib should be adjusted.The dose of imatinib was adjusted to 200 mg per day,and then increased to 300 mg per day.During the combination medication period, the blood concentration of imatinib was measured,and the adverse drug reactions were evaluated and monitored. Results Physicians adopted the recommendations of clinical pharmacists.During the combination therapy of voriconazole and imatinib, the patient's infection was well controlled. The blood concentration of imatinib showed 1372.08ng/mL, and the patient's liver function and blood routine were normal, and the condition was stable.the condition was stable. Conclusion The clinical pharmacist participated in the treatment process of this patient, formulated an individualized treatment plan and achieved good results, and provided ideas for the adjustment of drug dosage for the combination of imatinib and voriconazole.
Key words:  Acute lymphoblastic leukemia  Imatinib  Voriconazole  Clinical pharmacist  Pharmaceutical care
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.